A5059617228- Prostate Cancer Treatment and Research
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Computational Drug Discovery Methods
- Mass Spectrometry Techniques and Applications
- Cancer, Lipids, and Metabolism
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Hormonal and reproductive studies
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- Chemical Reactions and Isotopes
- Mathematical Biology Tumor Growth
- Cytokine Signaling Pathways and Interactions
- Salivary Gland Disorders and Functions
- Neonatal Health and Biochemistry
- Chemokine receptors and signaling
- Atomic and Subatomic Physics Research
- Antibiotics Pharmacokinetics and Efficacy
- Cannabis and Cannabinoid Research
- Adipose Tissue and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
National Research Council
2020-2023
Centro de Biología Molecular Severo Ochoa
2022
Universidad Autónoma de Madrid
2022
Medical University of Białystok
2019
In spite of the huge advancements in both diagnosis and interventions, hormone refractory prostate cancer (HRPC) remains a major hurdle (PCa). Metabolic reprogramming plays key role PCa oncogenesis resistance. However, dynamics between metabolism are not fully understood. Here, we demonstrate that two multi-target natural products, cannabidiol (CBD) cannabigerol (CBG), suppress HRPC development TRansgenic Adenocarcinoma Mouse Prostate (TRAMP) model by metabolic oncogenic signaling....
A better understanding of the complex crosstalk among key receptors and signaling pathways involved in cancer progression is needed to improve current therapies. We have investigated cell models representative major subtypes breast (BC) interplay between chemokine CXCL12/CXCR4/ACKR3 EGF receptor (EGFR) family cascades. These lines display a high heterogeneity expression profiles CXCR4/ACKR3 receptors, with predominant intracellular localization different proportions surface CXCR4+, ACKR3+ or...
Background: Adenosine is a nucleoside that impacts the cardiovascular system during or inflammatory diseases. The rapid determination of adenosine in blood may be useful emergency medicine especially syncope diagnose septic shock. We compare its measurement using fixed potential amperometry (FPA), with usual methods: mass spectrometry (LC-MS/MS) high performance liquid chromatography (HPLC). Methods: Twenty healthy subjects (14 men and 6 women) ten patients suffering from vasovagal (VVS,...
Introduction: As it is generally known, regulatory B cells (Bregs) control inflammation and autoimmunity. The significance of Bregs in the population children with autoimmune thyroid diseases (AITD) still offers plenty potential to explore. aim this study was estimate expression (phenotype CD19+CD24+CD27+IL-10+, CD19+IL-10+, CD1d+CD5+CD19+IL-10+ CD1d+CD5+CD19+CD24+CD27+) a paediatric cohort AITD health controls.Materials methods: A total 100 blood samples were obtained from 53 patients...
Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well patients previously exposed to chemotherapy. However, resistance enzalutamide and withdrawal syndrome have been reported. Thus, reliable integrated preclinical models are required elucidate mechanisms assess therapeutic settings that may delay or prevent onset resistance. In this study, multistage murine...
<p>The Figure shows the long term behavior of sensitive and resistant cells (in absence enzalutamide</p>
<p>Simulation and treatment of TRAMP mice treated with enzalutamide, cabazitaxel the combination</p>
<p>Time courses of pH and oxygen in presence enzalutamide continuous treatment</p>
<p>Simulation and treatment of TRAMP mice treated with enzalutamide, cabazitaxel the combination</p>
<p>Supplemantary informations for the model parameterization</p>
<div>Abstract<p>Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well patients previously exposed to chemotherapy. However, resistance enzalutamide and withdrawal syndrome have been reported. Thus, reliable integrated preclinical models are required elucidate mechanisms assess therapeutic settings that may delay or prevent onset resistance. In this...
<p>Sensitivity analysis</p>
<p>The Figure shows the long term behavior of sensitive and resistant cells (in absence enzalutamide</p>
<div>Abstract<p>Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well patients previously exposed to chemotherapy. However, resistance enzalutamide and withdrawal syndrome have been reported. Thus, reliable integrated preclinical models are required elucidate mechanisms assess therapeutic settings that may delay or prevent onset resistance. In this...
<p>Enzalutamide does not induce apoptosis in TRAMP-C2 cells</p>
<p>Time courses of pH and oxygen in presence enzalutamide continuous treatment</p>
<p>Additional Material and Methods</p>
<p>Additional Material and Methods</p>
<p>Sensitivity analysis</p>
<p>Supplemantary informations for the model parameterization</p>
<p>Enzalutamide does not induce apoptosis in TRAMP-C2 cells</p>